YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
The Invesco RAFI US 1500 Small-Mid ETF (PRFZ) was launched on September 20, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Small Cap Blend segment of the US equity market. The fund is sponsore…
* Arbutus Biopharma (ABUS [https://seekingalpha.com/symbol/ABUS]) traded higher on Wednesday after the antimicrobial drug developer announced plans to repurchase 46M shares of its common stock at $5 each as part of a previously disclosed t…
Roivant Sciences Ltd. (NASDAQ:ROIV) shares jumped about 17% after the company reported positive mid-stage results for mosliciguat, its experimental treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Th…
Immunovant Inc. Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Sever…
Roivant Sciences Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Seve…
Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 p…
[Scientists inside a laboratory] Hinterhaus Productions The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease…
Allegiant Travel Company (NASDAQ:ALGT) has declined year-to-date, but the airline's outlook is improving following the Sun Country Airlines acquisition. Wall Street is already taking note of the benefits in play, which are expected to unlo…
Roivant Sciences (NasdaqGS: ROIV) reported positive Phase 2 PHocus trial results for mosliciguat in PH-ILD patients. The study showed statistically significant and clinically meaningful changes in pulmonary vascular resistance and six-minu…
The Morning Bull - US Market Morning Update Wednesday, Sep, 16 2026 US stock futures are pointing slightly higher in early trade, with E-mini S&P 500 contracts up about 0.3% and tech heavy Nasdaq futures ahead roughly 0.4%. The big driver…
According to a September 9 Bloomberg report, Kinetik Holdings Inc. (NYSE:KNTK) is exploring strategic alternatives, including a potential sale, as midstream assets become increasingly attractive to infrastructure and energy buyers. Improvi…
Roivant Sciences Ltd. (NASDAQ:ROIV) shares surged 18% on September 8 after the biotech company reported strong Phase 2 results for an experimental treatment for pulmonary hypertension. The positive topline results from the Phase 2 PHocus t…
QUALCOMM Incorporated (QCOM) shares rose 3.2% on optimism over its new data center partnership with Amazon Web Services and its AI growth prospects. Roivant Sciences Ltd. (ROIV) shares surged18.8% after positive Phase 2 results for its pul…
Roivant Sciences Ltd. (NASDAQ:ROIV) soared to a new all-time high on Tuesday after reporting stellar results from the clinical trial of its treatment candidate for pulmonary hypertension associated with interstitial lung disease (PH-ILD).…
The S&P 500 Index ($SPX) (SPY) closed down -0.58% on Tuesday, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.12%. E-mini S&P futures (ESU26) fell -0.57%, and Septemb…
Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results for lung and swelling disease treatments. Continue Reading
Roivant Sciences (ROIV) shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Continue Reading
The S&P 500 Index ($SPX) (SPY) is down -0.32% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -1.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.04%. E-mini S&P futures (ESU26) are down -0.33%, and September E-mini Nas…
The S&P 500 Index ($SPX) (SPY) is down -0.34% today, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.83%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.19%. E-mini S&P futures (ESU26) are down -0.41%, and September E-mini Nas…
Pulmovant, a clinical-stage biotech and Roivant(NASDAQ:ROIV) company, on Tuesday shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD…
Check out the companies making the biggest moves premarket: Roivant Sciences — Shares rallied 24% after the pharma company said Phase 2 trial results for subsidiary Pulmovant's mosliciguat demonstrated "a clinically meaningful and statisti…
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-…
Roivant Sciences' (ROIV) Pulmovant unit's phase 2 PHocus study of mosliciguat in patients with pulmo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Pulmovant, Inc. PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever report…
Roivant Sciences PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p<0.0001) at Week 16, the highest ever repor…
Roivant Sciences Ltd. (NASDAQ:ROIV) and Priovant Therapeutics have moved quickly to commercialize Lisraya following its FDA approval for dermatomyositis. The partners launched the daily pill immediately and set a list price of $35,000 for…
Roivant Sciences Ltd. (NASDAQ:ROIV) and partner Priovant Therapeutics have secured FDA approval for Lisraya, the first oral treatment for dermatomyositis, which is a rare condition that causes painful skin rashes and progressive muscle wea…
Roivant Sciences BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hyper…
Pulmovant, Inc. WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today annou…
[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Priovant Therapeutics, a company backed by Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) and Roivant Sciences (ROIV [https://seeki…
Roivant Sciences LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune disease LISRAYA is a once-daily pill that directly targets key immune pathways i…
LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune disease LISRAYA is a once-daily pill that directly targets key immune pathways implicated in derm…
JAMA Dermatology publication includes results from VALOR skin-specific secondary endpoints, with rapid and durable improvements seen for brepocitinib 30 mg compared to placebo across multiple dimensions of cutaneous dermatomyositis (DM), i…
Roivant Sciences reported past first-quarter 2026 results, with sales of US$1.44 million versus US$2.17 million a year earlier and a narrower net loss of US$189.84 million, reducing basic loss per share from US$0.33 to US$0.26. The combina…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Roivant Sciences Stock Is In Focus After First Quarter Results Roivant Sciences (NasdaqGS:ROIV) is in focus after r…